Advances in the Management of Myeloma Parameswaran Hari, MD
|
|
- Lucy Summers
- 5 years ago
- Views:
Transcription
1 Advances in the Management of Myeloma Parameswaran Hari, MD Medical College of Wisconsin Milwaukee, WI
2 What is the standard? Induction/Transplant/Maintenance UPDATED OS DATA from CALGB & IFM REF:
3 Current Trials Exploring Interventions For Smoldering Multiple Myeloma Study Sponsor/Study Director Intervention Status ECOG-E3A06 NCT NCI/ S. Lonial Lenalidomide vs observation Currently recruiting NCT MSKC/ C.O. Landgren Ixazomib/dex x12 cycles followed by 24 cycles of maintenance for patients PR Currently recruiting NCT PETHEMA/ San Miguel & Mateos KRd x6 cycles stem cell collection KRd 2cycles Rd maintenance 24 cycles Currently recruiting NCT Janssen Research & Development 3 schedules of Daratumumab (Long intense, intermediate, short intense) Currently recruiting NCT MD Anderson/ Manasanch Pembrolizumab 200mg IV Q21d 24 cycles Not yet open NCT DFCI/ I. Ghobrial Elotuzumab/Lenalidomide +/- Dex Currently recruiting Eligibility criteria and definition of high risk SMM varies among trials
4 Questions in Induction / Transplant Does induction matter if transplant is planned? 3 drugs or 2 drugs for Induction Which 3 drugs steroids + PI + IMID vs others Can we do better with Induction? Role of autotransplant Early ; Delayed or Never? Maintenance / Consolidation After transplant Can we improve the current standard of transplant + Lenalidomide maintenance Special Groups Some thoughts on relapse
5 SWOG S0777 RVD vs. VD Newly diagnosed MM (transplant eligible and non-eligible patients) VRd Q21d x 8 cycles vs Rd Q28d x 6 cycles Rd maintenance Survival VRd (n = 242) Rd (n = 229) HR P Value Median PFS, months ( ).0018* Median OS, months ( ).025 Durie B, et al. ASH Abstract 25.
6 IFM Phase III Trial of VTD vs VCD induction VTD Arm (n = 169) Bortezomib 1.3 mg/m 2 /day SC Days 1, 4, 8, 11 + Thalidomide 100 mg/day PO Days Dexamethasone 40 mg/day PO Days 1-4, Days 9-12 VCD Arm (n = 169) Bortezomib 1.3 mg/m 2 /day SC Days 1, 4, 8, 11 + Cyclophosphamide 500 g/m 2 /day PO Days 1, 8, 15 + Dexamethasone 40 mg/day PO Days 1-4, Days 9-12 x4 cycles ASCT Response,* % VTD (n = 169) VCD (n = 169) P Value CR VGPR PR In per-protocol analysis, trend toward significantly higher numbers of CD34+ cells harvested for stem cell transplantation with VTD vs VCD x 10 6 vs 9.17 x 10 6 CD34+ cells/kg, respectively (P =.05) *Centralized assessment by IMWG criteria 2011 Primary endpoint Moreau P, et al. ASH Abstract 393.
7 Auto-Transplant vs. Novel Drugs - Modern Studies Group No Induction Comparator > VGPR GIMEMA NEJM 2014 MultiCente r Lancet Oncol 2015 IFM 2009 ASH 2015 EMN ASH RD x4 MPR x6 ASCT x2 389 RD x4 CDR x6 ASCT x2 700 VRD x3 VRD x5 ASCT + VRD x VCD x3-4 VMP x4 ASCT 1 or * 74 85* All of them are early vs. late transplant studies too PFS 22mo median 43mo* 29mo 43mo* 34mo 43mo* 3 yrs 65% HR 0.73* OS 65% 4y 81%* 68% 4y 77%* 83% 4y 81% NS (short fu)
8 Determination Trial Phase III IFM/DFCI 2009 Role of Early vs Delayed Transplant in the Era of Novel Agents MRD MRD N = 700 Pts 65 yrs of age Symptomatic, measurable NDMM VRd* 3 cycles VRd* 8 cycles MEL200 ASCT VRd* 2 cycles consolidation Lenalidomide Maintenance** Primary objective: PFS Secondary objectives: ORR, MRD, TTP, OS, Safety *VRD: bortezomib 1.3 mg/m 2 IV on Days 1, 4, 8, 11 + lenalidomide 25 mg on Days dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11, 12. ** till POD in US trial and 12 months in IFM trial Included PBSC collection with cyclophosphamide 3 g/m 2 + G-CSF after cycle 3. Avet-Loiseau H, et al. ASH Abstract 191.
9 IFM 2009 PFS / OS Response, % VRD Transplant CR VGPR MRD Neg FCM Attal M et al. N Engl J Med 2017;376:
10 IFM 2009 MRD Status
11 Treatment Schema MMRC U Chicago Protocols SCC + ASCT MRD at 8 cycles KRd+ASCT (4-week cycle) KRd induction (Cycles 1-4) KRd Consolidation (Cycles 5-8) KRd Maintenance (Cycles 9-18) MRD at 4 cycles Considered promising if scr improves from 30% to 50% at 8 cycles KRd w/o ASCT (4-week cycle) KRd induction (Cycles 1-4) KRd Consolidation (Cycles 5-8) KRd Maintenance (Cycles 9-24) SCC for eligible pts MRD at CR* MRD at 18 cycles LEN maintenance (off protocol) Zimmerman T et al ASH 2016; Abstract 675
12 Response Rates Over the Course of Treatment Aggressive Induction does not eliminate the need for ASCT KRd + ASCT KRd w/o ASCT Response, % cycles n=75 Response after ASCT (n=71) 11 8 cycles n=70 90% 44% 27% 21% 18 cycles n= cycles n= cycles 18 cycles n=44 n=41 VGPR ncr CR scr VGPR ncr CR scr KRd+ASCT shows high rates of deep responses in NDMM, with higher rates of scr compared with KRd w/o ASCT at pre-specified time point of 8 cycles 63% vs 30% Best response 74% vs 55%
13 Studies Included in Meta-Analysis CALGB (accrual 8/ /2009) IFM (accrual 6/2006 8/2008) GIMEMA (RV-MM-PI-209) (accrual 11/2007 7/2009) INDUCTION ASCT 1:1 RANDOMIZATION NO EVIDENCE OF PD INDUCTION ASCT 1:1 RANDOMIZATION NO EVIDENCE OF PD ASCT 2 2 DESIGN LEN + DEX 4 INDUCTION MPR: 6 COURSES LEN: 2 COURSES PLACEBO (n = 229) LEN Maint a (n = 231) PLACEBO (n = 307) LEN Maint a (n = 307) NO TREATMENT (n = 67) LEN Maint b (n = 67) NO TREATMENT LEN Maint b INTERIM ANALYSIS ANDINTERIM UNBLINDING ANALYSIS AND UNBLINDING Dec 2009 Dec 2009 Jan 2010 PRIMARY ANALYSIS CROSSOVER BEFORE PD ALLOWED CONTINUED TREATMENT NO CROSSOVER BEFORE PD ALLOWED CONTINUED TREATMENT ALL TREATMENT DISCONTINUED Jan 2011 CONTINUED TREATMENT Target population of patients with NDMM who received LEN maintenance or placebo/no maintenance after ASCT a Starting dose of 10 mg/day on days 1-28/28 was increased to 15 mg/day after 3 mos if tolerated and continued until PD. b Patients received 10 mg/day on days 1-21/28 until PD. ASCT, autologous stem cell transplant; LEN, lenalidomide; maint, maintenance; MPR, melphalan, prednisone, and lenalidomide; NDMM, newly diagnosed multiple myeloma; maint, maintenance; PD, progressive disease. CONTINUED TREATMENT Attal M et al ASCO 2016 McCarthy P et al EHA 2016 McCarthy P et al IMW 2017
14 Overall Survival: Median Follow-Up of 80 Months There is a 25% reduction in risk of death, representing an estimated 2.4- year increase in median survival (March 2015 data cutoff) a yr OS Survival Probability Events/n Median OS HR (95% CI) (95% CI), mo P value LEN maint 215/605 NR (NR-NR) 0.75 ( ) Placebo/.001 Observation 275/ ( ) Overall Survival (Months) No. at Risk LEN maint Placebo/ Observation a Log-rank test and Cox model stratified by study to assess impact of lenalidomide maintenance on overall survival. Median for lenalidomide treatment arm was extrapolated to be 115 months based on median of the control arm and HR (median, 86 months; HR = 0.75). HR, hazard ratio; maint, maintenance; NR, not reached; OS, overall survival. 50% 62% Attal M et al ASCO 2016 McCarthy P et al EHA 2016 McCarthy P et al IMW 2017
15 Summary Transplant is key Early better than collect and hold Induction matters as induction improves post transplant outcomes improved Lenalidomide maintenance benefits >> risk Standard of Care 3 drug induction (PI / IMID / Steroid) Melphalan based Auto Lenalidomide maintenance
16 Multiple Myeloma, Circa 2017 Treatment initiation dictated by presence of morbidity Therapy anchored on proteasome inhibitors, IMId and corticosteroids Treatment stratification based mostly in age One size fits all treatment approach Success defined by improvement in surrogates of gross disease Continuous therapy until failure/intolerance Most patients will die from MM
17 Newer Studies EU and US
18 Myeloma XI+ TE TNE R 1:1:2 Induction CTD Cyclophosphamide: 500mg d1,8,15 Thalidomide: mg daily Dexamethasone: 40mg d1-4,12-15 To max response/intolerance Dose reduced for TNE CRD Cyclophosphamide: 500mg d1,8 Lenalidomide: 25mg d1-21 Dexamethasone: 40mg d1-4,12-15 To max response/intolerance Dose reduced for TNE CCRD Cyclophosphamide: 500mg d1,8 Carfilzomib: 20/36 mg/m 2 d1-2,8-9,15-16 Lenalidomide: 25mg d1-21 Dexamethasone: 40mg d1-4,8-9,12-15 To max response/intolerance Not for TNE R 1:1 * Consolidation CVD Cyclophosphamide: 500mg d1,8,15 Velcade: 1.3mg/m 2 d1,4,8,11 Dexamethasone: 20mg d1-2,4-5,8-9,11-12 Dose reduction for TNE No further treatment ASCT (TE only) R 2:1 Lenalidomide No maintenance TE: Transplant eligible TNE: Transplant non-eligible Decision based on individual patient factors including age, co-morbidities and patient/clinician discussion. * Patients with NC/PD response to initial IMiD all received CVD consolidation
19 Transplant eligible Significant improvement in PFS from 28 to 50 months, HR=0.47 Median PFS, months [95% CI] 100 Lenalidomide (n=451) 50 [44, ] Patients alive and progression-free (%) Observation (n=377) 28 [23, 32] HR=0.47; 95% CI 0.38, 0.60 Log-rank p< Time since randomisation (months) No. of patients at risk: Lenalidomide Observation Jackson GH et al ASH 2016, Courtesy G Morgan
20 Daratumumab ASCT Hovon/IFM R Induction 4 cycles VTD + Dara VTD Endpoints: scr PFS, OS HDM ASCT Consolidation 2 cycles VTD + Dara VTD Stratify by: dara treatment, response, MRD status R Maintenance Until progression Dara Observation Courtesy P Sonneveld
21 Alliance Len +/-Daratumumab post ASCT for NDMM MEL 200 Auto Transplant RESTAGE D MRD & IP Lenalidomide Lenalidomide Daratumumab 1 year 2 years
22 Multiple Myeloma: US Cooperative Group Trials E3A06 Phase II S0777- Rd vs VRd E1A06 - MPT vs. MPR CTN 0702 Phase III CALGB Len vs PBO Stem Cell Transplant Asymptomatic & Early E3A06 R vs. Obs A Plasmacytoma Z vs ZI Induction Rx E1A11: CRd vs VRd S1211: VRd vs. VRd Elo BMTCTN 1302: High risk Allo DETERMINATION: RVD Early vs Late HSCT A:Rd vs Rd Dara for HSCT Ineligible A: RVd vs RVd Dara HSCT Eligible Non Transplant Consolidation Maintenance E1A11 R 2 yrs vs until PD BMT CTN 1401 Len vs Len DC Vaccine post Extension of R 0702 S:R vs RI post Auto? A: R Dara vs R post HSCT? Relapse S1304: K high vs, low dose A061202: PDI vs PD RRMM: no prior BMT PDI vs HSCT?
23 Survival and PFS after HCT Older patients derive similar benefit Sharma M et al; Biol Blood Marrow Transplant Nov;20(11):1796
24 Cox Regression Analysis of Overall Survival by HCT-CI score P=NS Cumulative Survival Out patient Transplant Experience at KU N= 448 pt ( ) Obiozor et al BBMT 2017 Follow Up (years)
25 Renal Impairment should not restrict HCT for MM Overall Survival (p-value=0.602) Probability, % Progression-free Survival (p-value=0.124) Normal/Mild Moderate Severe Years Mahindra A et al ASH abstract
26 Post induction + ASCT-1 followed by: BMT CTN0702 STaMINA Trial Results R Maint only n=257 RVD R n=254 Double ASCT R n=247 Median PFS, mos Median OS, mos High-risk patients, n mos mos Median PFS, Median OS, No significant difference between the study arms ClinicalTrials.gov. NCT
27 Dispenzieri A, et al. Mayo Clin Proc. 2007;82: Kumar SK, et al. Mayo Clin Proc. 2009;84: Mikhael JR, et al. Mayo Clin Proc. 2013;88: NCCN. Clinical practice guidelines in oncology: multiple myeloma. v Chng WJ, et al. Leukemia. 2014;28: MM Risk Categories Risk Factors FISH Cytogenetics Standard Risk (80%) (Expected OS: 6-7 Yrs) t(11;14), t(6;14) Hyperdiploidy High Risk (20%) (Expected OS: 2-3 Yrs) del(17p), t(4;14)* t(14;16), +1q21 Hypodiploidy del(13q) β 2 -microglobulin* Low (< 3.5 mg/l) High ( 5.5 mg/l) PCLI < 3% High ( 3%) Gene expression profile Good risk High risk Other high risk features: Extramedullary disease Plasma cell leukemia Plasmablastic morphology *Patients with t(4;14), β 2 -microglobulin < 4 mg/l, and Hb 10 g/dl may have intermediate-risk disease.
28 VRd Maintenance After ASCT in High Risk Disease 45 patients received VRd maintenance after ASCT for 2 years Bortezomib 1.3mg/m 2 weekly Lenalidomide 10mg d1-21 Dexamethasone 40mg weekly. High-risk Features n (%) Del 17p 19 (42) Del 1p 9 (20) T (4;14) 2 (5) T (14;16) 5 (11) PCL 11 (24) Others (aggressive presentation) 7 (16) > 1 Cytogenetic abnormalities 34 (75) PFS: 32 months 3-year OS: 93% Post-induction Response Post-ASCT day 60 Best Response Response scr% scr+cr % VGPR % ORR % SD % PD % from: Nooka, AK, et al. Leukemia ,
29 Non-Transplant Candidates Carefully evaluate transplant eligibility Moving target on who is eligible Assess after induction Medicare: Age NOT a barrier Moving beyond Lenalidomide/ Dec
30 SWOG S0777 Survival and Safety RVd vs. Rd Survival VRd (n = 242) Rd (n = 229) HR P Value Median PFS, months ( ).0018* Median OS, months ( ).025 Adverse Event Grade 3 AE Neurologic Pain Sensory Gastrointestinal VRd,% (n = 241) Rd, % (n = 226) SPM P Value < NR Durie B, et al. ASH Abstract 25.
31 Ongoing Studies For Newly Diagnosed MM Patients Ineligible For Transplant Study Sponsor/Study Director Intervention Status Eloquent-1 NCT Bristol-Myers Squibb/AbbVie Len/dex +/- Elotuzumab Ongoing, but not recruiting MAIA Trial NCT Janssen Research & Development, LLC Len/dex +/- Daratumumab Currently recruiting KEYNOTE-185 NCT Merck Sharp & Dohme Corp. Len/dex +/- Pembrolizumab Currently recruiting
32 MODERN TRIPLETS FOR RELAPSE Carfilzomib Len Dex Ixazomib Len Dex Elotuzumab Len Dex Daratumumab Len -Dex Vs. LEN - Dex Bortezomib Panabinostat Dex Bortezomib - Daratumumab- Dex Vs. BTZ - Dex
33 Summary of PFS Rd 10 KRd IRd EloRd 5 0 ASPIRE TOURMALINE ELOQUENT-2 Trial Design PFS Invest. arm PFS Rd arm HR ASPIRE Rd vs KRd 26.3mo 17.6mo 0.69 TOURMALINE Rd vs IRd 19.4mo 14.9mo 0.70 ELOUQUENT-2 Rd vs EloRd 20.6mo 14.7mo 0.74 Moreau, P. et al. ASH 2015 Abstract 727 Lonial, S. et al. N Engl J Med. 2015; 373: Stewart, et al. N Engl J Med. 2015;372:
34 VGPR Rates/PFS with Triplet vs Doublet Regimens Odds of Achieving VGPR in Early Relapse Trial Odds Ratio Lower Limit Upper Limit P-Value PANORAMA MM VAR/IFM ELOQUENT ASPIRE POOLED ODDS RATIO Odds Ratio and 95% CI for Achieving VGPR Doublet Better Triplet Better Pooled Hazards Ratio: PFS Trial Hazard Ratio Lower Limit Upper Limit z-value P-Value PANORAMA MM VAR/IFM Hazard Ratio and 95% CI for PFS ELOQUENT ASPIRE POOLED ODDS RATIO Nooka, et al. Blood. 2015;126: Triplet Better Doublet Better 34
35 MAb-Based Targeting of Myeloma Antibody-dependent cellular cytotoxicity (ADCC) Effector cells: FcR Complement-dependent cytotoxicity (CDC) C1q CDC MM C1q Apoptosis/growth arrest via targeting signaling pathways MM ADCC MM Daratumumab (CD38) SAR (CD38) Daratumumab (CD38) SAR (CD38) Elotuzumab (SLAMF7) Daratumumab (CD38) SAR (CD38) Tai YT, et al. Bone Marrow Res. 2011;2011:
36 CASTOR: Study Design Multicenter, randomized, open-label, active-controlled phase 3 study Key eligibility criteria RRMM 1 prior line of therapy Prior bortezomib exposure, but not refractory R A N D O M I Z E 1:1 DVd (n = 251) Daratumumab (16 mg/kg IV) Every week - cycle 1-3 Every 3 weeks - cycle 4-8 Every 4 weeks - cycles 9+ Vel: 1.3 mg/m 2 SC, days 1,4,8,11 - cycle 1-8 dex: 20 mg PO-IV, days 1,2,4,5,8,9,11,12 - cycle 1-8 Vd (n = 247) Vel: 1.3 mg/m 2 SC, days 1,4,8,11 - cycle 1-8 dex: 20 mg PO-IV, days 1,2,4,5,8,9,11,12 - cycle 1-8 Primary Endpoint PFS Secondary Endpoints TTP OS ORR, VGPR, CR MRD Time to response Duration of response Cycles 1-8: repeat every 21 days Cycles 9+: repeat every 28 days Daratumumab IV administered in 1000 ml to 500 ml; gradual escalation from 50 ml to 200 ml/min permitted RRMM, relapsed or refractory multiple myeloma; DVd, daratumumab/bortezomib/dexamethasone; IV, intravenous; Vel, bortezomib; SC, subcutaneous; dex, dexamethasone; PO, oral; Vd, bortezomib/dexamethasone; PFS, progression-free survival; TTP, time to progression; ORR, overall response rate; VGPR, very good partial response; CR, complete response; MRD, minimal residual disease. 36
37 Proportion surviving without progression No. at risk Vd DVd Progression-free Survival Months Median : 7.2 months HR: 0.39 (95% CI, ); P< *KM estimate; HR, hazard ratio Median : not reached year PFS* % 26.9% Vd 0 0 DVd 61% reduction in the risk of disease progression or death for DVd vs Vd
38 POLLUX LENALIDOMIDE + DARA
39 POLLUX STUDY
40 4 Major Triplets for Relapsed MM
41 We don t know which triplet is better KRD IRD ERD DRD DVD DPD Comparison of HR across trials is not the answer Odds of winning does not inform us about the margin of victory Triplet vs. Doublet designs looking at PFS are of marginal benefit to the field
42
43 ROLE OF RETRANSPLANTATION
44 Myeloma X: High-dose Melphalan + Salvage ASCT vs Cyclophosphamide in R/R MM R/R MM; > 18 mos after prior ASCT (N = 293) PAD induction 2-4 cycles Melphalan 200 mg/m2 IV + ASCT (n = 89) Cyclophosphamide 400 mg/m2/wk PO x 12 cycles (n = 85) PAD induction therapy: bortezomib + doxorubicin + dexamethasone 2-4 cycles PBSC mobilization and harvesting if applicable Removed from study if PD or CD34+ cells < 2 x 106/kg Primary endpoint: time to disease progression Secondary endpoints: OR, PFS, OS, toxicity, safety, pain, QoL Cook G, et al. Lancel Oncol. 2014;15:
45 Myeloma X: Salvage Transplant at Relapse Randomized 1:1 R/R MM; >18 mos after prior ASCT (N = 293) Cook G et al; Lancet Haematol Jul;3(7):e PAD induction 2-4 cycles Melphalan 200mg/m2 IV + ASCT (n = 89) Cyclophosphamide 400mg/m2 PO/wk x12 cycles (n = 85)
46 KEYNOTE-023: Efficacy of Pembrolizumab + Len/Dex in R/R MM All ResponseEvaluable Pts (n = 17) LenalidomideRefractory Pts (n = 9) ORR, n (%) VGPR PR 13 (76) 4 (24) 9 (53) 5 (56) 2 (22) 3 (33) Disease control rate, n (%) 15 (88) 7 (78) Outcome Median time to first response, mos (range) 1.2 ( ) M-protein reduction 50% from baseline, % 76.5 Median DoR, mos 9.7 San Miguel J, et al. ASH Abstract 505.
47 CHECK POINT INHIBITION AFTER ASCT Correlative Studies Effects of anti-pd-1 on T- and NK-cell function Correlation of immune cell phenotypes in the autologous graft and outcomes Study Schema Lenalidomide Transplant Pembrolizumab 200 mg IV Melphalan 0 * * Graft Sample Blood Samples CR conversion rate at day 180
48 Newer and Fancier Immunotherapy BCMA CAR-T cells CAR-BCMA T cells specifically recognized BCMA Exhibited antimyeloma activity in humans. Reliable Elimination of MM plasma cells Even works in chemotherapy refractory Need higher doses than CART19? Deep Remissions induced Toxicity incl. CRS Relapses noted despite CR Soluble BCMA Not a factor Syed Abbas Ali et al. Blood 2016;128:
49 BCMA CART early data 11 pts screened, and 6 treated in cohort 1. Grade 4 PRES Grade 3 CRS Adam D. Cohen et al. Blood 2016;128:1147
50 Allogeneic Transplantation can cure some patients with MM Graft versus Tumor Effect ( Allo Effect ) Graft versus Myeloma effect? Donor Lymphocyte infusion induce Tail of survival remission Chronic GVHD lowers relapse risk CRUDEST and OLDEST Immunotherapy for MM Prospect of long term disease control Agnostic to traditional risk markers Gahrton G et al N Engl J Med Oct 31;325(18):1267
51 Are there any pts who benefit from AlloHCT now? 1. High risk subset is allo better? Risk defined by.? When should allo be done? 2. Is an allogeneic immune system better for some pts? Can we use an allo immune system better as a platform for immune modulation?
52 Can upfront Allotransplant cure high risk? Author N HIGH RISK DEFINITION High risk Allo vs. Auto EBMT NMAM 92 Deletion 13 q PFS - 8 years 21% vs. 5% OS - 8 years 47% vs. 31% Knop 199 DEL 13q + DEL 17p Median PFS NR vs. 6 mo Median OS NR vs. 23 mo Hi Risk MM < 65 years N Tandem AUTO 1:1 Auto #1 Flu MEL +-ATG ALLO with Sib or URD (incl 9/10) Knop S et al; ASH abstract 2014 Dec #43 2-year PFS 59% vs. 47% with Auto. 2 Yr PFS
53 Post-relapse Survival: Is relapse after Allo different? Adjusted Probability, % 100 AUTO/AUTO vs. AUTO/ALLO ( 12 months after relapse) HR = 0.72( ) p-value = AutoAllo (n=178) AutoAuto (n=404) Identical 60 Results from randomized EBMT study Gahrton et al Blood Novel therapies augment immune response vs. MM and help in the setting of post allo relapse AUTO/AUTO vs. AUTO/ALLO (>12 months) 20 HR = 1.55( ) p-value = Years Htut et al 2016 ASH abstract
54 Patient selection: Early Relapse after Auto Consider Allo
55 Additional Agents Currently in Early Phase Development Agent MOA Clinical Trial Phase Ibrutinib Tyrosine kinase inhibitor (BTK, ERK1/2, others) I and II Filanesib Kinesin spindle protein inhibitor II Indatuximab ravtansine CD138 antibody-drug conjugate I and II HDAC inhibitor I and I/II XPO1 nuclear transport inhibitor I and II anti-cd38 antibody I/II Selective BCL-2 inhibitor I Ricolinostat Selinexor (KPT-330) MOR202 (MOR03087) Venetoclax Clinicaltrials.gov 55
Advances in the Management of Myeloma Parameswaran Hari, MD
Advances in the Management of Myeloma Parameswaran Hari, MD Armand J. Quick/William F. Stapp Professor of Hematology Director, Adult Blood and Marrow Transplant Program Froedtert Hospital Medical College
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationInduction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
More informationManaging Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
More informationConsolidation and Maintenance therapy
University of Salamanca Consolidation and Maintenance therapy María-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain Disclosure form MVM has served as member of advisory boards or received
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationLiving Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern
Living Well with Myeloma Teleconference Series Thursday, March 24 th 216 4: PM Pacific/5: PM Mountain 6: PM Central/7: PM Eastern Speakers Dr. Brian Durie, IMF Chairman Cedars Sinai Samuel Oschin Cancer
More informationMULTIPLE MYELOMA. TREATMENT in 2017 MC. VEKEMANS
MULTIPLE MYELOMA TREATMENT in 2017 MC. VEKEMANS NATURAL HISTORY of MM WHO SHOULD BE TREATED? DEFINITION MGUS Smouldering Multiple Myeloma Symptomatic Multiple Myeloma Monoclonal component (blood and/or
More informationMultiple myeloma, 25 (45) years of progress. The IFM experience in patients treated with frontline ASCT. Philippe Moreau, Nantes
Multiple myeloma, 25 (45) years of progress The IFM experience in patients treated with frontline ASCT Philippe Moreau, Nantes Shibata T. Prolonged survival in a case of multiple myeloma treated with high
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationCOMy Congress A New Era of Advances in Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
A New Era of Advances in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationAntibodies are a standard part of first relapse management in multiple myeloma (MM): Yes
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes Ajay Nooka, MD MPH FACP Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory
More informationBest of ASH 2017 DR. BRIAN DURIE. Brian GM Durie, MD Thursday, January 11, 2018
Best of ASH 2017 DR. BRIAN DURIE Brian GM Durie, MD Thursday, January 11, 2018 1 ASH Overview 2017 Total myeloma abstracts: 981 Important/Interesting: oral ~40 posters ~60 100 2 Which abstracts impact
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationContinuous Therapy as a Standard of Care CON. JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France
Continuous Therapy as a Standard of Care CON JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France 1 In France and in the IFM all debates 2 In France and in the IFM all debates
More informationRelapsed Myeloma Sequencing Treatments
Relapsed Myeloma Sequencing Treatments Noopur Raje, MD Director, Center for Multiple Myeloma MGH Cancer Center Professor of Medicine Harvard Medical School Disclosures Consultant /Advisory Board: Celgene,
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationNovel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma
Novel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma Ravi Vij, MD MBA Professor of Medicine Washington University School of Medicine Section of Stem Cell Transplant
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationMAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA. Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health
MAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health Disclosures I have no significant conflicts of interest to disclose.
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationMeu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin
Meu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin Post Auto HCT Options for MM Maintenance Lenalidomide vs.
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationTiming of Transplant for Multiple Myeloma
Timing of Transplant for Multiple Myeloma Wenming CHEN Beijing Chaoyang Hospital Capital Medical University Multiple myeloma resrarch center of Beijing Initial Approach to Treatment of Myeloma Nontransplantation
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationUK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook
UK Myeloma Research Alliance Myeloma XII study (ACCoRD): Augmented Conditioning & Consolidation in Relapsed Disease UK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook Sponsor ID: Pending
More informationInduction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program
Induction Therapy: Have a Plan Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Topics When to treat? Smoldering vs Symptomatic Risk stratification
More information2015 Updates in Multiple Myeloma
2015 Updates in Multiple Myeloma Siddhartha Ganguly, MD, FACP Professor of Medicine Director, Lymphoma and Myeloma Blood and Marrow Transplantation Program The University of Kansas Medical Center 1 Earliest
More informationHighlights in multiple myeloma
3 CONGRESS HIGHLIGHTS Highlights in multiple myeloma P. Vlummens, MD SUMMARY Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment
More informationCurrent management of multiple myeloma. Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School
Current management of multiple myeloma Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School JorgeJ_Castillo@dfci.harvard.edu Multiple myeloma MM is a plasma cell neoplasm characterized
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationManagement of Multiple Myeloma
Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.
More informationUpdates in Multiple Myeloma: 12 months in 10 minutes
Updates in Multiple Myeloma: 12 months in 10 minutes Aaron Rosenberg MD, MS Assistant Prof. Medicine UC Davis Comprehensive Cancer Center Division of Hematology and Oncology Outline Standard of care for
More informationTreatment Strategies for Transplant-ineligible NDMM Patients
1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily
More informationCurrent Management of Multiple Myeloma. December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C.
Current Management of Multiple Myeloma December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C. Disclosures Honoraria Speaker Celgene, Janssen, Novartis Celgene, Janssen Research Support Celgene
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationUpfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic
More informationTREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE
TREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE PRESENTED BY: Pooja Chaukiyal MD Hematologist/Oncologist New York Oncology Hematology Albany, NY April 16, 2016 Background The prognosis for patients
More informationMultiple Myeloma Highlights: 2016 ASH Annual Meeting Patient Webinar
2016 ASH Annual Meeting Patient Webinar January 11, 2017 1 Welcome and Introductions Anne Quinn Young, MPH Vice President, Development and Strategic Partnerships Multiple Myeloma Research Foundation 2
More informationMultiple Myeloma: Diagnosis and Primary Treatment
Multiple Myeloma: Diagnosis and Primary Treatment George Somlo, MD City of Hope Comprehensive Cancer Center NCCN.org For Clinicians NCCN.org/patients For Patients Educational Objectives Discuss considerations
More informationPost Transplant Maintenance- for everyone? Disclosures
Post Transplant Maintenance- for everyone? NO Because of limited survival data, not all patients require maintenance April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
More informationMultiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D.
Multiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D. Multiple Myeloma Facts Second most prevalent hematologic neoplasm Nearly 24, new cases diagnosed in the US per year and 11, worldwide
More informationMultiple Myeloma in 2016 Progress and Challenges DONNA E. REECE, M.D. PRINCESS MARGARET CANCER CENTRE 01 APRIL 2016
Multiple Myeloma in 2016 Progress and Challenges DONNA E. REECE, M.D. PRINCESS MARGARET CANCER CENTRE 01 APRIL 2016 Key Features of Myeloma Biology Myeloma is not one disease 1 At least 7 subtypes based
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationTreatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice
Treatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice Friday, December 2, 2016 San Diego, California This program is supported by educational grants from
More informationTo Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance
More informationNovel Therapies for the Treatment of Newly Diagnosed Multiple Myeloma
Novel Therapies for the Treatment of Newly Diagnosed Shaji K. Kumar, MD Professor of Medicine Mayo Clinic College of Medicine Consultant, Division of Hematology Medical Director, Cancer Clinical Research
More informationMyeloma Support Group: Now and the Horizon. Brian McClune, DO
Myeloma Support Group: Now and the Horizon Brian McClune, DO Disclosures Consultant to Celgene Objectives Transplant for myeloma- is there any thing new? High risk disease University protocols New therapies?
More informationChristine Chen Princess Margaret Cancer Centre September 2013
Christine Chen Princess Margaret Cancer Centre September 2013 Disclosures Research Support Celgene, Janssen, GSK Employee N/A Consultant N/A Major Stockholder Speakers Bureau/ Scientific Advisory Board
More informationMYELOMA MAINTENANCE BEST PRACTICES:
MYELOMA MAINTENANCE BEST PRACTICES: POST THERAPY & POST TRANSPLANT Aric Hall, MD Assistant Professor University of Wisconsin Hospital and Clinics INTRODUCTION MYELOMA Clonal plasma cell malignancy leading
More informationIntegration of Novel Therapy Into Myeloma Management
Updates on Diagnostic Criteria and Management of Multiple Myeloma Kenneth C. Anderson, MD Dana-Farber Cancer Institute Integration of Novel Therapy Into Myeloma Management Bortezomib, lenalidomide, thalidomide,
More informationMultiple Myeloma: Diagnosis, Prognosis, and Treatment. Jeffrey A. Zonder, MD Professor of Oncology Karmanos Cancer Institute
Multiple Myeloma: Diagnosis, Prognosis, and Treatment Jeffrey A. Zonder, MD Professor of Oncology Karmanos Cancer Institute General Themes Smoldering Myeloma: Diverging Philosophies Newly Diagnosed Myeloma:
More informationMyeloma: Are We on the Brink of a Cure? Jeffrey Wolf, MD Director, Myeloma Program University of California, San Francisco
Myeloma: Are We on the Brink of a Cure? Jeffrey Wolf, MD Director, Myeloma Program University of California, San Francisco Survival in Myeloma IFM DFCI; 2015 2011-14 2001-10 1961-70 1991-2000 Kumar S.
More informationNovel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones
More informationRecent Advances in the Treatment & Management of Relapsed Refractory Multiple Myeloma.
Recent Advances in the Treatment & Management of Relapsed Refractory Multiple Myeloma. Ajay Nooka MD MPH Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory University
More informationExperience with bortezomib (Velcade) in multiple myeloma. Peter Černelč Clinical center Ljubljana Department of Haematology
Experience with bortezomib (Velcade) in multiple myeloma Peter Černelč Clinical center Ljubljana Department of Haematology Our experience with bortezomib (Velcade) in multiple myeloma 1. Our first experience
More informationMultiple Myeloma Brian Berryman, M.D. March 8 th, 2014
Multiple Myeloma 2014 Brian Berryman, M.D. March 8 th, 2014 Kyle, R. A. et al. Blood 2008;111:2962-2972 Updates in Multiple Myeloma CCO Independent Conference Coverage of the 2013 Annual Meeting of
More informationTreatment of elderly patients with multiple myeloma
Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact
More informationStem Cell Transplant for Myeloma: The New Landscape
Stem Cell Transplant for Myeloma: The New Landscape Sergio A. Giralt, MD Chief, Adult Bone Marrow Transplant Service Division of Hematologic Oncology Department of Medicine Memorial Sloan-Kettering Cancer
More informationMaking Sense of Myeloma Treatment Advances
Making Sense of Myeloma Treatment Advances Webinar 1, May 17, 217 Updates From the 16th International Myeloma Workshop and the American Association for Cancer Research 217 Annual Meeting Speakers Moderator:
More informationChoosing upfront and salvage therapy for myeloma in the ASEAN context
Choosing upfront and salvage therapy for myeloma in the ASEAN context Daryl Tan Consultant Department of Haematology Singapore General Hospital Adjunct Assistant Professor Duke-NUS Graduate Medical School
More informationUpdates in the Treatment and Management of Relapsed/Refractory Multiple Myeloma
Updates in the Treatment and Management of Relapsed/Refractory Multiple Myeloma Rachid Baz, MD Associate Professor, Departments of Oncologic Sciences and Medicine University of South Florida Associate
More informationASCO Analyst & Investor Webcast. June 1, 2018
ASCO Analyst & Investor Webcast June 1, 2018 June 1, 2018 NASDAQ: BLUE Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information
More informationMultiple Myeloma in 2017 Making Sense of All of the Choices
Multiple Myeloma in 2017 Making Sense of All of the Choices TACOS March 2017 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC, FACP Associate Dean, Mayo School
More informationMultiple Myeloma Transplant and Non-transplant Modalities
Multiple Myeloma Transplant and Non-transplant Modalities Sikander Ailawadhi, MD Associate Professor of Medicine Division of Hematology-Oncology Mayo Clinic, Jacksonville, Florida 15 th Annual Miami Cancer
More informationAutologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy
Autologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy Donna E. Reece, M.D. Princess Margaret Hospital Toronto, ON CANADA 10 December 2011 ASCT in Myeloma..
More informationIs Myeloma Curable in 2012?
Is Myeloma Curable in 2012? YES Cure is living long enough to die of another cause April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist,
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationStato dell arte: dalle opzioni terapeutiche alla strategia terapeutica nel 2017
Stato dell arte: dalle opzioni terapeutiche alla strategia terapeutica nel 2017 Elena Zamagni Istituto di Ematologia Seragnoli Università di Bologna Eligibility for ASCT Yes Induction: 3-drug regimens
More informationRisk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
More informationOncology Highlights ASCO 2011 MULTIPLE MYELOMA
Oncology Highlights ASCO 211 MULTIPLE MYELOMA July 211 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist, Mayo Clinic Arizona Disclosures
More informationNew IMWG Response Criteria
New IMWG Response Criteria Shaji Kumar, M.D. Professor of Medicine Division of Hematology Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationMichel Delforge Belgium. New treatment options for multiple myeloma
Michel Delforge Belgium New treatment options for multiple myeloma Progress in the treatment of MM over the past 40 years 1962 Prednisone + melphalan 1990s Supportive care 1999 First report on thalidomide
More informationTreatment of Relapsed Myeloma Mayo Consensus
Treatment of Relapsed Myeloma Mayo Consensus Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive Cancer Center msmart Mayo Stratification
More informationModule 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning
Module 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning Challenge Question: Role of Autologous Stem Cell Transplant Which of the following is true about eligibility for high-dose
More informationNew Treatment Paradigms in Transplant-Eligible Myeloma Patients
New Treatment Paradigms in Transplant-Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Turkey, March 1 st 2013 NEW TREATMENT PARADıGM
More informationNew myeloma drugs improve response and extend survival
The JCSO Interview New myeloma drugs improve response and extend survival David H Henry, MD, a interviews Kenneth C Anderson, MD b a Department of Medicine, University of Pennsylvania Perelman School of
More informationManagement of Multiple
Management of Multiple Myeloma in the Elderly Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France INSERM U837, équipe 3 IRCL, CHRU, Lille, France IMPRT Institut de Médecine Prédictive
More information